(Q39974237)

16 September 2017

title

Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin (English)

1 reference

transitional cell carcinoma

16 September 2017

main subject

1 reference

Donghao Shang

1

1 reference

16 September 2017

Yuting Liu

2

1 reference

16 September 2017

Yoshiyuki Matsui

3

1 reference

16 September 2017

Noriyuki Ito

4

1 reference

16 September 2017

Hiroyuki Nishiyama

5

1 reference

16 September 2017

Toshiyuki Kamoto

6

1 reference

16 September 2017

Osamu Ogawa

7

1 reference

16 September 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

71

1 reference

16 September 2017

issue

6

1 reference

16 September 2017

page(s)

1220-1225

1 reference

Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

A Method for Testing for Synergy with Any Number of Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.11.029

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2007.11.029

1 reference

16 September 2017

1 reference